

Table 1. Multivariable logistic regression for DAS28-remission at 12 months.

Variable	n (%)	Univariable logistic regression		Multivariable logistic regression		
		OR (CI)	P	OR (CI)	SE	P
Anti-CarP	60 (60)	3.0 (1.31–6.88)	0.01	3.41 (1.08–10.7)	1.99	0.04
Serologies						
RF and anti-CCP negative	31 (33.0)			Reference		
Either RF or anti-CCP positive	11 (11.7)	0.99 (0.25–3.93)	0.99	1.10 (0.17–7.04)	1.04	0.92
RF and anti-CCP positive	52 (55.3)	1.12 (0.45–2.75)	0.80	0.89 (0.28–2.81)	0.52	0.84
Baseline disease activity						
Remission	17 (17.4)			Reference		
Low disease activity	10 (10.2)	0.50 (0.05–4.67)	0.54	0.13 (0.01–1.67)	0.17	0.12
Moderate disease activity	32 (32.7)	0.29 (0.05–1.65)	0.16	0.10 (0.02–0.68)	0.10	0.02
High disease activity	39 (39.8)	0.18 (0.04–0.90)	0.04	0.06 (0.01–0.41)	0.06	<0.01
Treatment						
csDMARD monotherapy	26 (26)	Reference				
Combination csDMARDs or bDMARD	74 (74)	1.13 (0.46–2.76)	0.80	1.97 (0.58–6.67)	1.23	0.28
Baseline radiographic damage	11 (20)	1.79 (0.65–4.95)	0.26	1.27 (0.33–4.95)	0.88	0.73
Tertiary education	23 (38.3)	0.77 (0.34–1.77)	0.54	0.42 (0.12–1.45)	0.27	0.17
Ethnicity						
Chinese	42 (70)			Reference		
Malay	39 (68.4)	0.61 (0.22–1.71)	0.35	0.56 (0.14–2.25)	0.40	0.41
Indian	8 (13.3)	0.60 (0.20–1.77)	0.35	0.79 (0.20–3.13)	0.56	0.74
Females	46 (76.7)	0.43 (0.17–1.11)	0.08	0.48 (0.13–1.85)	0.33	0.29

anti-CarP: anti-carbamylated protein antibody; anti-CCP: anti-citrullinated protein antibody; bDMARD: biologic disease-modifying anti-rheumatic drugs; CI: confidence interval; csDMARD: conventional synthetic disease-modifying anti-rheumatic drugs; OR: odds ratio; RF: rheumatoid factor; SE: standard error